Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.
NCT ID: NCT02045199
Last Updated: 2015-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
193 participants
INTERVENTIONAL
2014-02-28
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Differential Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds
NCT02347709
Patients With Diabetic Neuropathy Who Receive Physiotherapy Treatment Will Have a Decrease in Diabetic Foot Ulcers
NCT03725917
Surgical Decompression for Diabetic Neuropathy in the Foot
NCT01006915
Comparing the Ultrasound Appearance of the Sciatic Nerve With Its Appearance Under a Microscope
NCT02384447
Causes Associated With Small Fiber Neuropathy (SFN).
NCT04170205
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
V0111
Tested product : V0111 cream
Application twice a day during 28 days
Placebo
Placebo
Application twice a day during 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tested product : V0111 cream
Application twice a day during 28 days
Placebo
Application twice a day during 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cracked open heel with at least one fissure Grade 2,
Exclusion Criteria
* Major static disorder ,
* Ulceration and history of ulceration,
* Active haemorrhagic crack,
* Hyperkeratotic disease
* Diabetic arteriopathy,
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Medicament
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Garrigue, MD
Role: STUDY_DIRECTOR
Pierre Fabre Médicament
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brussels, , Belgium
Edegem, , Belgium
Liège, , Belgium
Angers, , France
Bron, , France
La Rochelle, , France
Laval, , France
Mantes-la-Jolie, , France
Muret, , France
Nanterre, , France
Nice, , France
Nieuls Sur Mer, , France
Paris, , France
Pessac, , France
Pringy, , France
Rillieux Village, , France
Saint-Orens-de-Gameville, , France
Seysses, , France
Suresnes, , France
Tiercé, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A01394-41
Identifier Type: OTHER
Identifier Source: secondary_id
V00111 CR 0 02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.